Pfeifer Andrea 4
4 · AC Immune SA · Filed May 18, 2026
Research Summary
AI-generated summary of this filing
AC Immune (ACIU) CEO Andrea Pfeifer Sells 10,000 Shares
What Happened
Andrea Pfeifer, Chief Executive Officer of AC Immune SA (ACIU), sold 10,000 common shares in an open‑market transaction on May 15, 2026. The reported weighted average price was $2.79 per share (range $2.75–$2.825), for total proceeds of $27,935. This was a sale (S), which is often routine insider selling and does not by itself indicate a change in company outlook.
Key Details
- Transaction date: May 15, 2026 (reported on Form 4 filed May 18, 2026) — filing appears timely.
- Price: Weighted average $2.79; reported price range $2.75 to $2.825 (footnote F1).
- Shares sold: 10,000; Proceeds: $27,935.
- Shares owned after transaction: not explicitly stated in the summary provided; filing footnote F2 notes holdings include 1,921,005 common shares underlying outstanding restricted share units.
- Footnotes: F1 explains the weighted average and multiple trade prices and offers to provide full breakdown on request; F2 discloses RSUs included in holdings.
- Transaction type: Open‑market sale (Form 4 code S).
Context
Sales by executives can be for many reasons (liquidity, diversification, tax obligations) and are not necessarily a signal about company fundamentals. This filing reports a straightforward open‑market sale; there is no indication in the filing of an option exercise, 10b5‑1 trading plan, or gifting related to this transaction.
Insider Transaction Report
- Sale
Common Share
[F1][F2]2026-05-15$2.79/sh−10,000$27,935→ 3,820,288 total
- 14,000(indirect: By Spouse)
Common Share
Footnotes (2)
- [F1]The price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.825. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F2]Includes 1,921,005 common shares underlying outstanding restricted share units.